News | November 08, 2022
SeQuent Scientific to acquire 100% stake in Tineta Pharma
The acquisition is for an enterprise value of Rs. 218 crores
The acquisition is for an enterprise value of Rs. 218 crores
The company will address the observations within a stipulated timeline working with the regulators
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
